InnoSer and Inficure Bio are announcing a strategic partnership to offer Inficure Bio’s spontaneous liver inflammation & fibrosis mouse model (NIF mouse) as part of InnoSer’s expanding cardiometabolic services portfolio.
The Umeå based life science company InfiCure Bio continues to take large steps in the global market by signing agreements with two major international companies.
“The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio”, says InfiCure Bio’s CEO, Sofia Mayans.
Inficure Bio a life science company focused on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions co-presented with CymaBay Therapeutics positive data at the American Association for the study of Liver Diseases (AASLD) using the company’s proprietary NIF mouse model.
Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.
“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.
Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.
Swedish Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases.
“We will now begin testing the effects of their drug substances in our unique model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia Mayans.
Umeå-based Inficure Bio is expanding again, as yet another employee is hired to meet the growing demand for the company’s products.
“Things are going really well for us right now and it feels like the perfect time to expand our team,” says Sofia Mayans, CEO of Inficure Bio.
Now the first company has left the incubator after going through all the steps in the incubator process – from Preincubate to Growth. Congratulations Inficure Bio – well done!
When Umeå’s big business gala was held on November 7, three of twelve awards went to life science.
“Previously, life science had a relatively hidden role in Umeå – but during this year’s Umeågala we have proven that we are an industry that has great potential”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Umeå-based Inficure Bio signed the biggest deal in the company’s history back in April. Now they have signed a new deal – which is twice as large.
“This is a fantastic opportunity for us. Deals like this demonstrate that our international credibility is increasing”, says Sofia Mayans, CEO of Inficure Bio.
Life science company Inficure Bio attract millions in new funding round.
“Attracting new investment allows us to move faster. We have lots of potential customers and we want to launch new applications for our product”, says Sofia Mayans, CEO of Umeå-based Inficure Bio.
Umeå-based life science company Inficure Bio has appointed Lena Söderström, who was previously in charge at stock exchange listed company Senzime, as its new chairman of the board of directors.
Umeå-based life science company Inficure Bio has just won the largest contract in its history.
“It feels incredible! The more large customers we get the greater our credibility becomes. This agreement is a real feather in our cap”, says Sofia Mayans, CEO of Inficure Bio.
Life science company Inficure Bio has been awarded millions by Vinnova to support the company’s development of a model that will help create new treatments for fibrosis.
“This money is incredibly important to us. Thanks to this investment we can now finish developing a new product”, says Sofia Mayans, CEO of Inficure Bio.
Inficure Bio has developed a new mouse model, the N-IF model. Mice are used as model organisms for studying human biology due to the genetic and physiological conformity between mice and humans. N-IF mice are unique as they spontaneously develop pathological fibrosis, rather than it being induced. This pathological progress is therefore more natural and provides better and faster results.
Inficure Bio has signed an investment deal acquiring external venture capital for the first time. The new partners contribute with broad competence and funding – and within one year the goal is to become an established player on the international market for development of anti-inflammatory and antifibrotic drugs.
A few weeks ago, Sofia Mayans, CEO of the startup InfiCure Bio, got an offer she could not turn down. Her successful participation in the “Entreprenour of the Future” last year had attracted some international attention – and suddenly she was the only woman out of eight CEO’s closing the bell at Nasdaq in New York City.
Quretech, Hiloprobe and Inficure made the 30th of March a day to remember for Umeå Biotech Incubator. Beeing at three different events, in three parts of Sweden – they all managed to take home the main prize. An unprecedented hat trick that shows how strong the startup portfolio from Umeå really is.
The business coaches at Umeå Biotech Incubator have collected an impressive know-how over the years. With their inside position of some of the most innovative medical solusions they know how to get a life science company to thrive and grow.
